| 臺大學術典藏 |
2022-01-24T09:31:47Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Kao J.-H.; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:45Z |
Impact of Genetic Heterogeneity in Polymerase of Hepatitis B Virus on Dynamics of Viral Load and Hepatitis B Progression
|
Huang C.-J.; Wu C.-F.; Lan C.-Y.; Sung F.-Y.; Lin C.-L.; CHUN-JEN LIU; Liu H.-F.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:44Z |
Identification of a liver cirrhosis signature in plasma for predicting hepatocellular carcinoma risk in a population-based cohort of hepatitis B carriers
|
Liu C.-C.; Wang Y.-H.; Chuang E.Y.; Tsai M.-H.; Chuang Y.-H.; Lin C.-L.; CHUN-JEN LIU; Hsiao B.-Y.; Lin S.-M.; Liu L.-Y.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:38Z |
Circulating programmed death-1 as a marker for sustained high hepatitis b viral load and risk of hepatocellular carcinoma e95870
|
Cheng H.-Y.; Kang P.-J.; Chuang Y.-H.; Wang Y.-H.; Jan M.-C.; Wu C.-F.; Lin C.-L.; CHUN-JEN LIU; Liaw Y.-F.; Lin S.-M.; Chen P.-J.; Lee S.-D.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:37Z |
Serum biomarkers predictive of significant fibrosis and cirrhosis in chronic hepatitis B
|
Lin C.-L.; Liu C.-H.; Wang C.-C.; Liang C.-C.; Su T.-H.; CHUN-JEN LIU; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:36Z |
Comparison of abbott realtime HCV genotype II with versant line probe assay 2.0 for hepatitis C virus genotyping
|
Liu C.-H.; Liang C.-C.; CHUN-JEN LIU; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:35Z |
Development of risk scoring system for stratifying population for hepatocellular carcinoma screening
|
Hung Y.-C.; Lin C.-L.; CHUN-JEN LIU; Hung H.; Lin S.-M.; Lee S.-D.; Chen P.-J.; Chuang S.-C.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:34Z |
Peginterferon plus weight-based ribavirin for treatment-na?ve hepatitis C virus genotype 2 patients not achieving rapid virologic response: A randomized trial
|
Liu C.-H.; Huang C.-F.; CHUN-JEN LIU; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:32Z |
Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Na?ve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial
|
Liu C.-H.; Huang C.-F.; CHUN-JEN LIU; Dai C.-Y.; Huang J.-F.; Lin J.-W.; Liang C.-C.; Yang S.-S.; Lin C.-L.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Kao J.-H.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:28Z |
Progressive accumulation of mutations in the hepatitis B virus genome and its impact on time to diagnosis of hepatocellular carcinoma
|
Sung F.-Y.; Lan C.-Y.; Huang C.-J.; Lin C.-L.; CHUN-JEN LIU; Chen P.; Lin S.-M.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:25Z |
Genome-wide identification of blood DNA methylation patterns associated with early-onset hepatocellular carcinoma development in hepatitis B carriers
|
Kao W.-Y.; Yang S.-H.; Liu W.-J.; Yeh M.-Y.; Lin C.-L.; CHUN-JEN LIU; Huang C.-J.; Lin S.-M.; Lee S.-D.; Chen P.-J.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:24Z |
Influence of Metabolic Risk Factors on Risk of Hepatocellular Carcinoma and Liver-Related Death in Men With Chronic Hepatitis B: A Large Cohort Study
|
Yu M.-W.; Lin C.-L.; CHUN-JEN LIU; Yang S.-H.; Tseng Y.-L.; Wu C.-F. |
| 臺大學術典藏 |
2022-01-24T09:31:15Z |
Smoking and Hepatitis B Virus–Related Hepatocellular Carcinoma Risk: The Mediating Roles of Viral Load and Alanine Aminotransferase
|
Wang Y.-H.; Chuang Y.-H.; Wu C.-F.; Jan M.-C.; Wu W.-J.; Lin C.-L.; CHUN-JEN LIU; Yang Y.-C.; Chen P.-J.; Lin S.-M.; Tsai M.-H.; Huang Y.-W.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; CHUN-JEN LIU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
Longitudinal change of metabolite profile and its relation to multiple risk factors for the risk of developing hepatitis B-related hepatocellular carcinoma
|
Huang B.-Y.; Tsai M.-R.; Hsu J.-K.; Lin C.-Y.; Lin C.-L.; Hu J.-T.; Huang Y.-W.; CHUN-JEN LIU; Wu W.-J.; Wu C.-F.; Sung F.-Y.; Chen P.-J.; Liang H.-J.; Lin S.-M.; Yu M.-W. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; Hsu S.-J.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatic steatosis and development of type 2 diabetes: Impact of chronic hepatitis B and viral specific factors
|
Yu M.-W.; Lin C.-L.; CHUN-JEN LIU; Huang Y.-W.; Hu J.-T.; Wu W.-J.; Wu C.-F. |
| 臺大學術典藏 |
2022-01-24T09:30:59Z |
Sofosbuvir/Velpatasvir for Hepatitis?C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; CHUN-JEN LIU; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; Hsu C.; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 臺大學術典藏 |
2022-01-24T09:30:57Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; CHUN-JEN LIU; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:52Z |
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan
|
Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Kao J.-H.; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:51Z |
Entecavir Prevents HBV Reactivation During Direct Acting Antivirals for HCV/HBV Dual Infection: A Randomized Trial
|
Cheng P.-N.; CHUN-JEN LIU; Chen C.-Y.; Tseng K.-C.; Lo C.-C.; Peng C.-Y.; Lin C.-L.; Chiu H.-C.; Chiu Y.-C.; Chen P.-J. |
| 臺大學術典藏 |
2022-01-24T06:05:35Z |
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan
|
Shao Y.-Y.; Wang S.-Y.; Lin S.-M.; Chen K.-Y.; Tseng J.-H.; Ho M.-C.; Lee R.-C.; Liang P.-C.; Liao L.-Y.; Huang K.-W.; Hu J.-T.; Liang J.-D.; Kee K.-M.; Lin C.-L.; Wang C.-K.; Lu S.-N.; Wang J.-H.; Lee W.-C.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Wang C.-C.; Wang T.-E.; Chuang P.-H.; Dai C.-Y.; CHIUN HSU; Chen S.-C.; Hsieh C.-H.; Diagnosis Group, Systemic Therapy Group |
| 國立成功大學 |
2022 |
Generative Adversarial Network (GAN) for Automatic Reconstruction of the 3D Spine Structure by Using Simulated Bi-Planar X-ray Images
|
Yang, C.-J.;Lin, C.-L.;Wang, C.-K.;Wang, J.-Y.;Chen, Chen C.-C.;Su, F.-C.;Lee, Y.-J.;Lui, C.-C.;Yeh, L.-R.;Fang, Y.-H.D. |
